Compare CRSR & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRSR | IMMX |
|---|---|---|
| Founded | 1994 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 616.0M | 528.0M |
| IPO Year | 2020 | 2021 |
| Metric | CRSR | IMMX |
|---|---|---|
| Price | $7.83 | $9.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | $8.50 | ★ $19.20 |
| AVG Volume (30 Days) | ★ 981.5K | 691.9K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.37 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $1,472,480,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.90 | N/A |
| P/E Ratio | $71.36 | ★ N/A |
| Revenue Growth | ★ 11.86 | N/A |
| 52 Week Low | $4.48 | $1.87 |
| 52 Week High | $10.29 | $11.61 |
| Indicator | CRSR | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 78.32 | 53.53 |
| Support Level | $7.35 | $8.15 |
| Resistance Level | $8.31 | $10.53 |
| Average True Range (ATR) | 0.38 | 0.71 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 78.33 | 67.56 |
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue-generating segment; and Gaming Components and Systems. Geographically, the group derives revenue from the Americas, Europe and the Middle East, and the Asia Pacific.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.